Unresolved issues, including different staining protocols, different antibody protocols, and different scoring methods for identifying target cells as TCs, tumor-infiltrating immune cells (TIICs), etc., likely contribute to the unstable PD-L1 landscape. The gene discussed is CD274; the disease is neoplasm.